Company News

Page of ( Articles)

MRCF funding for OncoRes Medical June 6, 2017
OncoRes Medical, a new Western Australian medical device company established to develop an imaging tool to improve the outcome of breast cancer surgery, will receive up to $6 million of venture capital investment from the MRCF.
World’s most decorated Olympian joins Medibio Board June 6, 2017
The world's greatest ever olympic gold medal winner Michael Phelps has been appointed to the Board of Australia medical technology company Medibio (ASX:MEB)
First investment from BTF May 30, 2017
The development of a new treatment for peanut allergy in children will be the first project to receive $10 million in funding under the Biomedical Translation Fund.
First cohort of patients approach end of therapy session May 30, 2017
Neurotech International (ASX:NTI), developer of medical solutions in the neuroscience space, has announced the clinical trial for Mente Autism has progressed as planned with investigators now...
PharmAust reports preliminary results from monepantel trial in dogs May 23, 2017
PharmAust (ASX:PAA) says it has received preliminary analysis from its Phase 2 dog lymphoma trial that showed three out of four dogs treated with Monepantel (MPL) achieved stable disease and reduction in tumour size.
MRCF and Uniseed invest in respiratory start-up Innavac May 23, 2017
Innavac has secured $6.3 million venture capital support from the Brandon Capital managed Medical Research Commercialisation Fund and Uniseed.
Avita Board takes fees as shares May 23, 2017
The Board of pioneering regenerative medicine company Avita Medical (ASX:AVH) have agreed to take part or all of their Director’s fees in the form of shares. According to the company, the...
Paradigm welcomes new publication May 23, 2017
Paradigm Biopharmaceuticals (ASX:PAR) has announced the peer reviewed publication validating the efficacy of PPS in experimental allergic rhinitis using an industry standard preclinical model.
Patient treatment commences in Cynata clinical trial May 18, 2017
Australian stem cell and regenerative medicine company, Cynata Therapeutics (ASX:CYP), has announced the first patient has been treated with CYP-001, its first mesenchymal stem cell (MSC)...
Specialised Therapeutics adds compound to portfolio May 18, 2017
Melbourne-based Specialised Therapeutics Asia (ST Asia) is set to commercialise a new anti-cancer drug in South East Asia after signing a second major licensing deal with European pharmaceutical...
BI extends development of Pharmaxis compound May 16, 2017
A major boost for Pharmaxis (ASX:PXS) with Boehringer Ingelheim extending its development of the Sydney-based company's PXS‐4728A. Boehringer Ingelheim acquired PXS‐4728A from Pharmaxis in...
Recognition for IDT Australia at manufacturing awards May 11, 2017
Boronia-based IDT Australia has won the Growth Sector – Medical Technologies and Pharmaceuticals category award at the 2017 Victorian Manufacturing Hall of Fame. Member for Eastern Metropolitan...

Page of ( Articles)

Company News

Most Read

New Australian collaboration for Johnson & Johnson

Government announces new investment in gene therapy

Review of national innovation metrics

Nominations open for research awards

Biogen and Eisai scrap development of Alzheimer's therapy

New Stories

Nominations open for research awards

Government announces new investment in gene therapy

Review of national innovation metrics

New Australian collaboration for Johnson & Johnson

Biogen and Eisai scrap development of Alzheimer's therapy

'Extending' the 'promise of immunotherapy'

GSK announces Australian winners of research challenge

Sign In

Most Read

New Australian collaboration for Johnson & Johnson

Government announces new investment in gene therapy

Review of national innovation metrics

Nominations open for research awards

Biogen and Eisai scrap development of Alzheimer's therapy

Follow Us

New Stories

Nominations open for research awards

Government announces new investment in gene therapy

Review of national innovation metrics

New Australian collaboration for Johnson & Johnson

Biogen and Eisai scrap development of Alzheimer's therapy

'Extending' the 'promise of immunotherapy'

GSK announces Australian winners of research challenge